01—Abstract
Summary
Summary of the 8-K filed February 10, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) reported fourth-quarter and full-year 2025 results in a press release furnished as Exhibit 99.1 to this Item 2.02 Form 8-K, dated February 10, 2026.
Total revenues were $598.7 milliona for the fourth quarter and $2,320.1 million for the fiscal year 2025, versus $566.8 million and $2,168.7 million in the comparable 2024 periods. Net product revenues rose to $546.6 million in the quarter and $2,122.8 million for the year, driven primarily by higher sales volume, while collaboration revenues fell for the year to $197.3 million from $359.3 million, mainly on lower milestone revenues and development cost reimbursements. GAAP diluted EPS was $0.88 for the quarter and $2.78 for the year; non-GAAP diluted EPS, which excludes stock-based compensation, was $0.94 and $3.08, respectively.
For 2026, Exelixis is maintaining its prior guidance of $2.525 billion to $2.625 billionb in total revenues and $2.325 billion to $2.425 billion in net product revenues. This guidance excludes any revenue from a potential U.S. launch of zanzalintinib in previously treated metastatic colorectal cancer (CRC) when combined with atezolizumab. The FDA accepted the zanzalintinib NDA with a standard review and a PDUFA target action date of December 3, 2026.
The company also expects topline STELLAR-303 (overall survival in non-liver metastases patients) and STELLAR-304 data in mid-2026, and plans to start the STELLAR-316 and STELLAR-201 trials in mid-2026. Capital return was active: Exelixis repurchased $264.5 millionc of stock in the fourth quarter at an average price of $43.17 per share, completed its $500 million program, and began executing a new $750 million authorization that runs through December 31, 2026.
02—Key points
Key Highlights
- Fourth-quarter 2025 total revenues of $598.7 million and GAAP diluted EPS of $0.88; fiscal 2025 total revenues of $2,320.1 million and GAAP diluted EPS of $2.78
- Net product revenues of $2,122.8 million for fiscal 2025, up from $1,809.4 million, primarily due to higher sales volume; U.S. cabozantinib franchise net product revenues were $2,122.8 million for the year
- Collaboration revenues declined to $197.3 million for fiscal 2025 from $359.3 million, reflecting lower milestone revenues and development cost reimbursements, partly offset by higher Ipsen royalties
- 2026 guidance maintained: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion, excluding potential zanzalintinib CRC launch revenue
- FDA accepted the zanzalintinib NDA in combination with atezolizumab for previously treated metastatic CRC, with a standard review and PDUFA target date of December 3, 2026
- Repurchased $264.5 million of stock in Q4 2025 at an average of $43.17 per share, completed the $500 million program, and began a new $750 million authorization expiring December 31, 2026
- Key 2026 milestones include STELLAR-303 and STELLAR-304 data in mid-2026, and initiation of STELLAR-316 and STELLAR-201 in mid-2026
03—Questions
Frequently Asked Questions
How did Exelixis's revenue perform in 2025?
Total revenues were $2,320.1 million for fiscal 2025, compared with $2,168.7 million in 2024. Net product revenues grew to $2,122.8 million from $1,809.4 million, primarily on higher sales volume. Collaboration revenues fell to $197.3 million from $359.3 million, mainly due to lower milestone revenues and development cost reimbursements.
What is Exelixis guiding for 2026?
Exelixis maintained its 2026 guidance: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion. Guidance does not reflect any revenue from a potential U.S. launch of zanzalintinib in metastatic colorectal cancer. Research and development expenses are guided to $875 million to $925 million, and SG&A to $575 million to $625 million.
When is the FDA decision expected on zanzalintinib for colorectal cancer?
The FDA accepted the NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic CRC under a standard review. The PDUFA target action date is December 3, 2026.
What share repurchase activity did Exelixis complete?
In Q4 2025, Exelixis repurchased $264.5 million of common stock at an average of $43.17 per share and completed its $500 million program authorized in February 2025. In October 2025, the board authorized up to an additional $750 million of repurchases before December 31, 2026, and repurchases under this program began in Q4 2025.
What clinical readouts are expected in 2026?
Exelixis expects the overall survival results for STELLAR-303 in patients without liver metastases and topline results from STELLAR-304 in advanced non-clear cell RCC, both in mid-2026 based on current event rates. It also plans to initiate STELLAR-316 in mid-2026 and STELLAR-201 in recurrent meningioma in mid-2026.
04—Continue